Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The health status alters the pituitary function and reproduction of mice in a Cxcr2-dependent manner.

Timaxian C, Raymond-Letron I, Bouclier C, Gulliver L, Le Corre L, Chébli K, Guillou A, Mollard P, Balabanian K, Lazennec G.

Life Sci Alliance. 2020 Feb 10;3(3). pii: e201900599. doi: 10.26508/lsa.201900599. Print 2020 Mar.

2.

Recent discoveries concerning the tumor - mesenchymal stem cell interactions.

Lazennec G, Lam PY.

Biochim Biophys Acta. 2016 Dec;1866(2):290-299. doi: 10.1016/j.bbcan.2016.10.004. Epub 2016 Oct 14. Review.

3.

IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production.

Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G.

Oncotarget. 2015 Oct 6;6(30):29034-47. doi: 10.18632/oncotarget.4732.

4.

Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects.

Plé C, Fan Y, Ait Yahia S, Vorng H, Everaere L, Chenivesse C, Balsamelli J, Azzaoui I, de Nadai P, Wallaert B, Lazennec G, Tsicopoulos A.

PLoS One. 2015 Apr 10;10(4):e0122372. doi: 10.1371/journal.pone.0122372. eCollection 2015.

5.

Chromatin remodeling protein SMAR1 regulates NF-κB dependent Interleukin-8 transcription in breast cancer.

Malonia SK, Yadav B, Sinha S, Lazennec G, Chattopadhyay S.

Int J Biochem Cell Biol. 2014 Oct;55:220-6. doi: 10.1016/j.biocel.2014.09.008. Epub 2014 Sep 18.

PMID:
25239884
6.

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer.

Boissière-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le Pessot F, Sabourin JC, Bibeau F.

Oncoimmunology. 2014 Jun 25;3:e29256. eCollection 2014.

7.

Estrogen receptor signaling as a target for novel breast cancer therapeutics.

Renoir JM, Marsaud V, Lazennec G.

Biochem Pharmacol. 2013 Feb 15;85(4):449-65. doi: 10.1016/j.bcp.2012.10.018. Epub 2012 Oct 24. Review.

8.

Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer.

Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K, Lazennec G.

PLoS One. 2012;7(9):e44787. doi: 10.1371/journal.pone.0044787. Epub 2012 Sep 6. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/480acc26-456b-4e06-8cb6-2834bd6f5553.

9.

[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

Ray-Coquard I, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F.

Bull Cancer. 2012 Apr 1;99(4):479-98. doi: 10.1684/bdc.2012.1558. Review. French.

10.

Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression.

Vogel CF, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y, Matsumura F.

Arch Biochem Biophys. 2011 Aug 1;512(1):78-86. doi: 10.1016/j.abb.2011.05.011. Epub 2011 May 26.

11.

[Mesenchymal stem cells: weapons or dangers for cancer treatment?].

Lazennec G.

Med Sci (Paris). 2011 Mar;27(3):285-8. doi: 10.1051/medsci/2011273285. Epub 2011 Mar 30. Review. French.

12.

Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer.

Vindrieux D, Le Corre L, Hsieh JT, Métivier R, Escobar P, Caicedo A, Brigitte M, Lazennec G.

Endocr Relat Cancer. 2011 Apr 2;18(3):311-21. doi: 10.1530/ERC-10-0230. Print 2011 Jun.

PMID:
21389059
13.

Chemokines and chemokine receptors: new insights into cancer-related inflammation.

Lazennec G, Richmond A.

Trends Mol Med. 2010 Mar;16(3):133-44. doi: 10.1016/j.molmed.2010.01.003. Epub 2010 Feb 15. Review.

14.

Emerging roles of chemokines in prostate cancer.

Vindrieux D, Escobar P, Lazennec G.

Endocr Relat Cancer. 2009 Sep;16(3):663-73. doi: 10.1677/ERC-09-0109. Epub 2009 Jun 25. Review.

PMID:
19556286
15.

CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.

Chavey C, Lazennec G, Lagarrigue S, Clapé C, Iankova I, Teyssier J, Annicotte JS, Schmidt J, Mataki C, Yamamoto H, Sanches R, Guma A, Stich V, Vitkova M, Jardin-Watelet B, Renard E, Strieter R, Tuthill A, Hotamisligil GS, Vidal-Puig A, Zorzano A, Langin D, Fajas L.

Cell Metab. 2009 Apr;9(4):339-49. doi: 10.1016/j.cmet.2009.03.002.

16.

Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer.

Rial NS, Lazennec G, Prasad AR, Krouse RS, Lance P, Gerner EW.

Int J Cancer. 2009 May 15;124(10):2270-80. doi: 10.1002/ijc.24226.

17.

Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer.

Chavey C, Mühlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, Jobin C, Lazennec G.

Mol Pharmacol. 2008 Nov;74(5):1359-66. doi: 10.1124/mol.108.047332. Epub 2008 Jul 30.

PMID:
18669446
18.

Expression of estrogen receptors alpha and beta in early steps of human breast carcinogenesis.

Roger P, Esslimani-Sahla M, Delfour C, Lazennec G, Rochefort H, Maudelonde T.

Adv Exp Med Biol. 2008;617:139-48. doi: 10.1007/978-0-387-69080-3_13. Review. No abstract available.

PMID:
18497038
19.

[Multipotent stromal cells: controversial impact on tumor development and metastasis].

Apparailly F, Jorgensen C, Lazennec G.

Med Sci (Paris). 2008 Apr;24(4):359-60. doi: 10.1051/medsci/2008244359. French. No abstract available.

20.

Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Lazennec G, Jorgensen C.

Stem Cells. 2008 Jun;26(6):1387-94. doi: 10.1634/stemcells.2007-1006. Epub 2008 Apr 3. Review.

21.

CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation.

Amura CR, Brodsky KS, Gitomer B, McFann K, Lazennec G, Nichols MT, Jani A, Schrier RW, Doctor RB.

Am J Physiol Cell Physiol. 2008 Mar;294(3):C786-96. doi: 10.1152/ajpcell.00457.2007. Epub 2008 Jan 16.

22.

CXC chemokines located in the 4q21 region are up-regulated in breast cancer.

Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretière JM, Burlinchon S, Lidereau R, Lazennec G.

Endocr Relat Cancer. 2007 Dec;14(4):1039-52.

23.

Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta.

Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A.

Mol Endocrinol. 2008 Feb;22(2):317-30. Epub 2007 Oct 25.

24.

High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.

Marot D, Bieche I, Aumas C, Esselin S, Bouquet C, Vacher S, Lazennec G, Perricaudet M, Kuttenn F, Lidereau R, de Roux N.

Endocr Relat Cancer. 2007 Sep;14(3):691-702.

PMID:
17914099
25.

RelB, a new partner of aryl hydrocarbon receptor-mediated transcription.

Vogel CF, Sciullo E, Li W, Wong P, Lazennec G, Matsumura F.

Mol Endocrinol. 2007 Dec;21(12):2941-55. Epub 2007 Sep 6.

26.

Chemokines: novel targets for breast cancer metastasis.

Ali S, Lazennec G.

Cancer Metastasis Rev. 2007 Dec;26(3-4):401-20. Review.

27.

Oestrogen receptor negative breast cancers exhibit high cytokine content.

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, Lazennec G.

Breast Cancer Res. 2007;9(1):R15.

28.

Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells.

Henriquet C, Gougat C, Combes A, Lazennec G, Mathieu M.

Lung Cancer. 2007 May;56(2):167-74. Epub 2007 Jan 17.

29.
30.

Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus.

Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M.

J Endocrinol. 2006 Jan;188(1):91-9.

PMID:
16394178
31.

Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8.

Kim SW, Hayashi M, Lo JF, Fearns C, Xiang R, Lazennec G, Yang Y, Lee JD.

Cancer Res. 2005 Oct 1;65(19):8784-91.

32.

ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Duong V, Licznar A, Margueron R, Boulle N, Busson M, Lacroix M, Katzenellenbogen BS, Cavaillès V, Lazennec G.

Oncogene. 2006 Mar 16;25(12):1799-806.

33.

The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene.

Annicotte JS, Chavey C, Servant N, Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F, Maudelonde T, Lazennec G, Cavailles V, Fajas L.

Oncogene. 2005 Dec 8;24(55):8167-75.

34.

Retraction: article on estrogen receptor beta in ovarian carcinogenesis.

Lazennec G.

Cancer Res. 2005 Jun 15;65(12):5480. No abstract available.

35.

Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P.

Endocr Relat Cancer. 2004 Sep;11(3):537-51. Review.

36.

Involvement of estrogen receptor beta in ovarian carcinogenesis.

Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G.

Cancer Res. 2004 Aug 15;64(16):5861-9. Retraction in: Lazennec G. Cancer Res. 2005 Jun 15;65(12):5480.

37.

Mechanisms underlying differential expression of interleukin-8 in breast cancer cells.

Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F, Lazennec G.

Oncogene. 2004 Aug 12;23(36):6105-14.

38.
39.

Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor.

Licznar A, Caporali S, Lucas A, Weisz A, Vignon F, Lazennec G.

FEBS Lett. 2003 Oct 23;553(3):445-50.

40.
41.

Comparative transductions of breast cancer cells by three DNA viruses.

Lucas A, Kremer EJ, Hemmi S, Luis J, Vignon F, Lazennec G.

Biochem Biophys Res Commun. 2003 Oct 3;309(4):1011-6.

PMID:
13679075
42.

IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G.

Oncogene. 2003 Jan 16;22(2):256-65.

43.

Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells.

Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H, Pujol P.

Oncogene. 2002 Feb 7;21(7):1097-107.

44.

ER beta inhibits proliferation and invasion of breast cancer cells.

Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F.

Endocrinology. 2001 Sep;142(9):4120-30.

46.
47.

Estrogen receptors: selective ligands, partners, and distinctive pharmacology.

Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA.

Recent Prog Horm Res. 2000;55:163-93; discussion 194-5. Review.

PMID:
11036937
48.
50.

Supplemental Content

Loading ...
Support Center